NeuroSense Therapeutics Ltd NRSN
News
NeuroSense Provides Update on Nasdaq Listing Compliance
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
NeuroSense Provides Business Update and Progress for the First Half of 2026
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
NeuroSense Issues CEO Letter to Shareholders
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
